New Jersey State Board of Dentistry
Alerts
Page Content
Scam Alert
The Division of Consumer Affairs (Division) is warning all licensed professionals about individuals impersonating New Jersey Division of Consumer Affairs (DCA) investigators, Drug Enforcement Administration (DEA) agents, DEA investigators, New Jersey Drug Control Unit investigators, Federal Bureau of Investigation (FBI) investigators, and other law enforcement personnel, as part of an extortion scheme. The impersonators are contacting licensees by telephone or letter, stating that they are the subject of an investigation. The callers are demanding money to clear up the matter, or threatening to revoke the individual's license. Please be advised that the Division of Consumer Affairs will not contact licensees by telephone to discuss investigations or demand money. Anyone receiving a telephone call from a person purporting to be any of the above mentioned individuals seeking money, should refuse the demand. We encourage you to report the call to the Federal Trade Commission (FTC) at
ReportFraud.ftc.gov. You may also report the call to the Division at
AskConsumerAffairs@lps.state.nj.us.
|
|
Notice Regarding Drug Take Back Programs
P.L. 2015, c.66, which becomes effective on January 1, 2016, requires prescribers and pharmacies to provide a notice about drug take back programs to each patient receiving a controlled dangerous substance (CDS) prescription.
View Notice (12/20/15) |
|
Electronic Prescribing of Controlled Substances (EPCS) for a Practitioner
On January 7, 2013 the Board of Pharmacy and Drug Control Unit adopted rules to allow prescribers to issue Schedule II controlled substances prescriptions electronically in accordance with federal requirements. New Jersey practitioners and pharmacies can utilize EPCS for all patient prescriptions.
View EPCS Information (10/5/2015) |
|
Physician Issuance of Multiple Prescriptions for Schedule II Controlled Substances
The New Jersey Division of Consumer Affairs is re-issuing the following guidance regarding the issuance of multiple prescriptions of a Schedule II controlled dangerous substance by a physician to a patient
View Guidance
(10/5/15) |
|
Information About the New NJ PMP Law.
In July, Senate Bill 1998 was signed into law (P.L.2015, c.74) which substantially revises the scope and expands the capabilities of the New Jersey Prescription Monitoring Program (NJPMP). The Division of Consumer Affairs is tasked with implementing the new law, which takes effect on November 1, 2015.
View Notice
(9/2015) |
Last Modified: 3/20/2024 10:52 AM
